Currently, approximately three-to-five percent (3-5%) of the T-cells Infused into a patient enter the Tumor Micro-Environment from the blood vasculature. This means 95% of the cells generated are wasted or, worse, rampage through the body causing side effects.
TZ 102 Enables Tumor Infiltrating Lymphocytes (TILs) to ‘home’, that is, to be directed to the tumor micro-environment more effectively from the blood vasculature by improving Tumor Infiltrating Lymphocyte cell rolling, tethering on the endothelial cells of the blood vessels and promoting their extravasation through the blood-vessel walls, enabling their transmigration into the tumor micro-environment. This results in 300-500% more T-cells reaching the tumor-micro-environment
In addition to enabling 300-500% more T-cells to enter the tumor-micro-environment from the blood stream, TZ 102 increases T-cell binding to tumors and increases T-Cell intra-tumor penetration. TZ 102 also increases the number of T-cells expressing FASL and intracellular Granzyme B and Perforin, all consistent with enhanced T-cell cytoxicity for increased tumor killing.
Approximately 3-5 Percent of the T-cells Typically Enter the Tumor Micro-Environment from the Blood Stream whereupon CAR, TCR enable T-cells to better target the Cancer Cells